NCT05792462Active, not recruitingPhase 1
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- First submitted
- 18 Mar 2023
- Start date
- 15 Apr 2023
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Tianjin Medical University General Hospital
- Diseases
- Neuromyelitis optica (NMOSD)
- NCT number
- NCT05792462
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 11
- From 15 Apr 2023 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, Hepatitis viruses, Syphilis, etc);
- Tumor disease currently or within the last 5 years;
- Patients with clinically relevant heart, liver, kidney or bone marrow dysfunction;
- History of venous thromboembolism (VTE), or are considered at high risk for VTE by the investigator.
Other
- Participation in another interventional study within the last 3 months;
- Pregnancy, breastfeeding, or child-bearing potential during the course of the study;
Who the study is looking for
- Male or female patients ≥ 18 years old;
- Diagnosis of NMO or NMO spectrum disorder according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria;
- Clinical evidence of either at least one relapse requiring rescue therapy (intravenous corticosteroids, intravenous immunoglobulin, plasma exchange or a combination of these therapies) in the year before screening or at least two relapses requiring rescue therapy in the 2 years before screening;
- Expanded disability status scale (EDSS) score ≤ 6.0;
- Patients were seropositive for AQP4-IgG;
- Able and willing to give written informed consent and comply with the requirements of the study protocol.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University General Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.